Orforglipron Interactions: Alcohol, Caffeine, Food and Other Compounds

Orforglipron is a non-peptide, small-molecule oral glucagon-like peptide-1 (GLP-1) receptor agonist, first characterised in humans in a phase 1a blinded, placebo-controlled, randomised single- and multiple-ascending-dose study in healthy participants (PMID 37344954). Because it is a small molecule rather than a peptide, the questions researchers ask about co-administration differ from those asked of injectable peptide agonists, and the published record on those questions is uneven: one question has a dedicated study, most have none.

This page separates the two. It describes what studies actually examined, and — where no interaction study exists — it states that plainly and then outlines the mechanistic reasoning investigators apply, clearly labelled as reasoning rather than measured data. This page is for educational purposes only and is not medical advice; consult a licensed physician about anything relating to medication, combinations, or health decisions.

What "interaction" means in the orforglipron literature

In the published orforglipron record, the word covers at least three different ideas that are easily conflated:

• Pharmacokinetic interaction — whether a co-ingested substance changes how much orforglipron is absorbed or how long it persists. Phase 1a work in healthy participants characterised the exposure profile that such questions are measured against (PMID 37344954), and a phase 1b multiple-ascending-dose study did the same in people with type 2 diabetes (PMID 37264711).
• Pharmacodynamic overlap — whether two substances act on the same physiology, such as appetite signalling or glucose handling, in ways that add up. Reviews of gut hormones and appetite regulation describe the receptor-level pathways involved (PMID 38511400).
• Tolerability overlap — whether two substances produce similar gastrointestinal effects, so that the combined experience is harder to attribute to either. A living systematic review and network meta-analysis for the American College of Physicians catalogued gastrointestinal events as the dominant harm class reported across pharmacologic obesity treatments (PMID 42296503).

Only the first of these is settled by a formal interaction trial for any of the substances discussed below, and only for food.

Food and fasting: the one question with a dedicated study

A published study specifically examined the effect of food consumption on the pharmacokinetics, safety, and tolerability of once-daily orally administered orforglipron, and the authors reported that the compound could be administered without regard to food or water intake (PMID 38402332). That finding is the single most frequently cited interaction result in the orforglipron literature, and it is the reason food-timing questions have a documented answer while alcohol and caffeine questions do not.

Reviews of novel GLP-1-based medications for type 2 diabetes and obesity have framed this absence of administration constraints as a distinguishing feature of small-molecule oral agonists compared with peptide-based oral formulations, which depend more heavily on absorption conditions in the stomach (PMID 41054801). A systematic review of emerging pharmacotherapies for obesity made a similar structural point when grouping non-peptide oral agents separately from injectable and peptide-based ones (PMID 39952695).

Fasting, meal size and appetite

Food-effect pharmacokinetics is a separate question from what happens to eating behaviour. Reviews of gut hormone biology describe GLP-1 receptor signalling as acting on satiety and gastric emptying, which is the mechanism by which appetite changes are explained (PMID 38511400). A phase 2 multicentre, randomised, dose-response study in patients with type 2 diabetes reported reductions in both HbA1c and body weight with once-daily oral orforglipron at doses studied up to 45 mg (PMID 37369232). No study in this verified set measured meal composition, intermittent fasting schedules, or ketogenic patterns alongside orforglipron.

Alcohol: what the literature does and does not report

No published trial in the verified literature administered alcohol together with orforglipron or measured an alcohol–orforglipron interaction. The phase 1a study in healthy participants and the phase 1b study in people with type 2 diabetes both characterised safety, tolerability and pharmacokinetics without an alcohol challenge component (PMID 37344954; PMID 37264711). Claims that orforglipron "reduces alcohol cravings" are not supported by an orforglipron study in this set.

The mechanistic reasoning researchers use (reasoning, not data)

The interest in this question comes from class-level pharmacology rather than orforglipron-specific findings. A German-language review asked whether GLP-1 receptor agonists represent a new pharmacological treatment option for psychiatric illnesses, surveying the hypothesis that GLP-1 signalling touches reward-related circuitry (PMID 40042613). Reviews of gut hormones and appetite regulation similarly describe central appetite and reward pathways as targets of gut-derived signals (PMID 38511400). Extrapolating from class reasoning to an orforglipron-specific alcohol effect is a hypothesis, and this page labels it as such.

A second strand of reasoning concerns tolerability rather than reward. Because gastrointestinal events were the most commonly reported adverse events in orforglipron trials (PMID 37369232), and because alcohol independently irritates the gastrointestinal tract, investigators note that overlapping symptoms would be difficult to attribute. That is an attribution problem described in the abstract, not a measured interaction.

Caffeine and other stimulants

No study in this verified set examined caffeine, coffee, energy drinks, or nicotine alongside orforglipron. The phase 1a single- and multiple-ascending-dose programme in healthy participants did not include a stimulant co-administration arm (PMID 37344954), and the food-effect study addressed food and water rather than caffeinated beverages specifically (PMID 38402332).

The mechanistic reasoning offered for why the question is asked at all rests on gastric emptying: reviews of incretin-based therapies describe slowed gastric emptying as part of the class mechanism (PMID 40604322), and slowed emptying is the general route by which the rate of absorption of co-ingested substances could plausibly change. That is a mechanistic inference about a class property, not an orforglipron–caffeine measurement, and no quantitative statement can be made from the verified papers.

Other medicines and compounds

Glucose-lowering agents

Orforglipron has been studied head-to-head against another GLP-1-based oral therapy: ACHIEVE-3, a multinational, multicentre, non-inferiority, open-label, randomised phase 3 trial, compared once-daily oral orforglipron with oral semaglutide in adults with type 2 diabetes (PMID 41765029). Comparison trials establish relative efficacy and safety; they are not combination studies, and no verified paper here administered two GLP-1 receptor agonists together. Narrative reviews of novel GLP-1-based medications discuss where such agents sit relative to existing glucose-lowering classes (PMID 41054801).

Other oral drugs

Questions about oral contraceptives, thyroid replacement, anticoagulants and similar narrow-window oral drugs are common. The verified set contains no dedicated drug–drug interaction study for orforglipron with any of these. The reasoning researchers apply is again the gastric-emptying mechanism described for incretin-based therapies generally (PMID 40604322), together with the observation from the food-effect study that orforglipron's own absorption was not constrained by food or water conditions (PMID 38402332). The regulatory documentation accompanying approval is the usual source for product-specific co-administration labelling; the approval itself is summarised in a first-approval review (PMID 42479349).

Supplements, research peptides and "stacks"

No study in this verified set combined orforglipron with creatine, berberine, other research peptides, or any dietary supplement. Systematic reviews of emerging obesity pharmacotherapy catalogue agents individually and by trial, not as combinations of a prescription agonist with unregulated products (PMID 39952695). Any statement about such combinations would be extrapolation with no measured basis.

Adverse Events Relevant to Combination Questions: What Studies Report

Interaction questions frequently arise because two substances produce similar symptoms. The phase 2 dose-response study in type 2 diabetes reported that gastrointestinal adverse events — nausea, vomiting, diarrhoea and related symptoms — were the most common adverse events, and that they were generally mild to moderate and dose-related (PMID 37369232). The phase 1b multiple-ascending-dose study in people with type 2 diabetes similarly characterised safety and tolerability as part of its primary objectives (PMID 37264711), as did the phase 1a study in healthy participants (PMID 37344954).

At a class level, the living systematic review and network meta-analysis for the American College of Physicians assessed both benefits and harms of pharmacologic treatments in adults with overweight or obesity, with gastrointestinal events prominent among reported harms (PMID 42296503). The practical consequence researchers note is one of attribution: when a second substance with overlapping gastrointestinal effects is present, the source of a symptom cannot be resolved from the trial data.

Evidence map

How to read the gaps

An absence of interaction data is not a finding of no interaction, and it is not a finding of harm either — it is an absence. Phase 1 programmes are designed to characterise dose, exposure and tolerability before broader co-administration questions are addressed, which is what the healthy-participant and type 2 diabetes ascending-dose studies did (PMID 37344954; PMID 37264711). Later-phase work, including the head-to-head phase 3 comparison with oral semaglutide, focused on efficacy and safety endpoints rather than substance co-administration (PMID 41765029). Product labelling attached to regulatory approval, summarised in the first-approval review, remains the reference document for co-administration information (PMID 42479349).

For background on the compound itself — its mechanism, trial programme and reported outcomes — see the overview at PeptideU's orforglipron learn page.

References

• Effect of Food Consumption on the Pharmacokinetics, Safety, and Tolerability of Once-Daily Orally Administered Orforglipron (LY3502970), a Non-peptide GLP-1 Receptor Agonist (Diabetes Therapy, 2024)
• Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1a, blinded, placebo-controlled, randomized, single- and multiple-ascending-dose study in healthy participants (Diabetes, Obesity & Metabolism, 2023)
• Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1b, multicentre, blinded, placebo-controlled, randomized, multiple-ascending-dose study in people with type 2 diabetes (Diabetes, Obesity & Metabolism, 2023)
• Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study (Lancet, 2023)
• Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial (Lancet, 2026)
• Orforglipron: First Approval (Drugs, 2026)
• Gut hormones and appetite regulation (Current Opinion in Endocrinology, Diabetes, and Obesity, 2024)
• Incretin-based therapies for the treatment of obesity-related diseases (npj Metabolic Health and Disease, 2024)
• Emerging pharmacotherapies for obesity: A systematic review (Pharmacological Reviews, 2025)
• Novel GLP-1-based Medications for Type 2 Diabetes and Obesity (Endocrine Reviews, 2026)
• Benefits and Harms of Pharmacologic Treatments in Adults With Overweight or Obesity: A Living Systematic Review and Network Meta-analysis for the American College of Physicians (Annals of Internal Medicine, 2026)
• Glucagon-like peptide-1 receptor agonists: a new pharmacological treatment option for psychiatric illnesses? (Der Nervenarzt, 2025)